Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Management of CRS related to teclistamab in patients with relapsed/refractory myeloma can be successful with as little as one dexamethasone dose of 10 mg and without compromising the response rate.”
Authors: James Davis, Jordan Snyder, Mikhaila Rice, Zahra Mahmoudjafari, Victoria Nachar et al.
More posts featuring Robert Orlowski.
